HC Wainwright Has Bullish Estimate for Agenus Q4 Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at HC Wainwright raised their Q4 2024 earnings estimates for Agenus in a report released on Thursday, December 5th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings per share of ($2.62) for the quarter, up from their previous forecast of ($2.88). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($6.85) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($6.45) EPS and FY2028 earnings at ($6.70) EPS.

Separately, B. Riley lowered their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Agenus presently has an average rating of “Hold” and an average target price of $10.00.

Agenus Stock Down 4.1 %

Shares of NASDAQ:AGEN opened at $3.36 on Monday. Agenus has a 52-week low of $2.50 and a 52-week high of $19.69. The company has a 50 day moving average of $3.91 and a two-hundred day moving average of $7.64. The company has a market capitalization of $78.71 million, a price-to-earnings ratio of -0.30 and a beta of 1.25.

Hedge Funds Weigh In On Agenus

Several institutional investors and hedge funds have recently made changes to their positions in AGEN. Vanguard Group Inc. boosted its stake in shares of Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after buying an additional 4,134,232 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares during the last quarter. Ovata Capital Management Ltd bought a new position in Agenus during the 2nd quarter worth approximately $670,000. Federated Hermes Inc. acquired a new stake in shares of Agenus during the 2nd quarter valued at approximately $1,921,000. Finally, Blair William & Co. IL bought a new stake in Agenus during the second quarter valued at $441,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.